227 related articles for article (PubMed ID: 32378285)
41. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
[TBL] [Abstract][Full Text] [Related]
42. The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase.
Aguiar JP; Alves da Costa F; Egberts T; Leufkens H; Souverein P
Eur Neuropsychopharmacol; 2020 Jun; 35():30-38. PubMed ID: 32409260
[TBL] [Abstract][Full Text] [Related]
43. According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world.
de Leon J
Br J Clin Pharmacol; 2022 Dec; 88(12):5434-5435. PubMed ID: 36106607
[No Abstract] [Full Text] [Related]
44. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
45. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
Kumlien E; Lundberg PO
Seizure; 2010 Mar; 19(2):69-73. PubMed ID: 20036167
[TBL] [Abstract][Full Text] [Related]
46. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal medical records as a complement to routine drug safety signal analysis.
Star K; Watson S; Sandberg L; Johansson J; Edwards IR
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):486-94. PubMed ID: 25623045
[TBL] [Abstract][Full Text] [Related]
49. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.
Sartori D; Aronson JK; Onakpoya IJ
Syst Rev; 2020 Aug; 9(1):180. PubMed ID: 32791982
[TBL] [Abstract][Full Text] [Related]
50. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase
Noseda R; Bedussi F; Gobbi C; Ceschi A; Zecca C
J Headache Pain; 2024 Jan; 25(1):10. PubMed ID: 38243189
[TBL] [Abstract][Full Text] [Related]
51. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
Kant A; de Vries L; Rolfes L
Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
[TBL] [Abstract][Full Text] [Related]
52. Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance.
Lupattelli A; Spigset O; Nordeng H
Int J Clin Pharm; 2018 Aug; 40(4):783-786. PubMed ID: 29948744
[TBL] [Abstract][Full Text] [Related]
53. Drug induced stuttering: pharmacovigilance data.
Trenque T; Morel A; Trenque A; Azzouz B
Expert Opin Drug Saf; 2021 Mar; 20(3):373-378. PubMed ID: 33337944
[No Abstract] [Full Text] [Related]
54. Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase
Linselle M; Sommet A; Bondon-Guitton E; Moulis F; Durrieu G; Benevent J; Rousseau V; Chebane L; Bagheri H; Montastruc F; Montastruc JL
Fundam Clin Pharmacol; 2017 Jun; 31(3):359-366. PubMed ID: 28036099
[TBL] [Abstract][Full Text] [Related]
55. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
56. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
57. Obstetric and neonatal outcomes of clozapine exposure in pregnancy: a consecutive case series.
Nguyen T; Mordecai J; Watt F; Frayne J
Arch Womens Ment Health; 2020 Jun; 23(3):441-445. PubMed ID: 31203441
[TBL] [Abstract][Full Text] [Related]
58. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
[TBL] [Abstract][Full Text] [Related]
59. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
60. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone.
Ye JH; Ho YF; On AW; Chen WW; Huang YM; Huang WI; Tang YW
Int J Clin Pharm; 2018 Aug; 40(4):911-920. PubMed ID: 30051228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
